Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT versus vancomycin for recurrent or refractory Clostridioides difficile infection
ACTRN12624000133538Phase 3Recruiting
- Sponsor
- The University of Auckland
- Start
- Jun 2024
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of allogeneic fecal microbiota and vancomycin in Clostridioides difficile colitis (CDI) and Clostridioides difficile infection (CDI), sponsored by The University of Auckland. Primary endpoint: Rate of sustained Clostridioides difficile infection cure at 12 weeks. Started Jun 2024; status: recruiting.
02
Drugs
allogeneic fecal microbiotavancomycin
03
Conditions
Clostridioides difficile colitis (CDI)Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on ACTRN12624000133538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000133538.